Evidence map›Paper›PMID 40351513›Full record

ArticleJournal of clinical tuberculosis and other mycobacterial diseases2025

Rifampicin-resistant

Gizeaddis Belay, Hailu Getachew, Tigist Birku, Aimro Tadese, Yosef Gashaw, Michael Getie, Tazeb Molla, Molalign Tarekegn, Daniel Mekonnen, Alemayehu Abate

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical tuberculosis and other mycobacterial diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gizeaddis BelayDepartment of Medical Microbiology, Amhara National Regional State Public Health Institute, Bahir Dar, Ethiopia.
Hailu GetachewDepartment of Medical Microbiology, Amhara National Regional State Public Health Institute, Bahir Dar, Ethiopia.
Tigist BirkuDepartment of Medical Microbiology, Amhara National Regional State Public Health Institute, Bahir Dar, Ethiopia.
Aimro TadeseDepartment of Tropical and Infectious Disease, Amhara National Regional State Public Health Institute, Bahir Dar, Ethiopia.
Yosef GashawRegional TB Laboratory System Strengthening and EQA Technical Advisor, Amhara National Regional State Public Health Institute, Bahir Dar, Ethiopia.
Michael GetieDepartment of Medical Microbiology, Amhara National Regional State Public Health Institute, Bahir Dar, Ethiopia.
Tazeb MollaDepartment of Medical Microbiology, Amhara National Regional State Public Health Institute, Bahir Dar, Ethiopia.
Molalign TarekegnDepartment of Medical Microbiology, Amhara National Regional State Public Health Institute, Bahir Dar, Ethiopia.
Daniel MekonnenDepartment of Medical Laboratory Sciences, School of Health Science, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia.
Alemayehu AbateLaboratory Director, Amhara National Regional State Public Health Institute, Bahir Dar, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Tuberculosis, an infectious disease caused by Methods: Retrospective data archived in the Amhara Public Health Institute (APHI) TB laboratory from 2019 to 2024 were reviewed. Xpert MTB/RIF-Ultra software data were retrieved and transferred to Microsoft Excel. Then, it was checked for completeness, cleaned manually, and imported to Statistical Package for the Social Sciences (SPSS) version 25 software. The rate of Results: From June 30, 2019, to June 30, 2024, a total of 587,128 sputum samples were obtained from presumptive TB patients in 111 GeneXpert sites in the Amhara Region. Of these samples analyzed using Xpert MTB/RIF-Ultra, 6.17 % (36,212/587,128) were Mtb positive. Furthermore, the overall proportion of rifampicin resistance (RR) among Mtb-confirmed cases decreased to 3.03 % (1,096/36,212) and showed a downward trend from 4.62 % (184/3979) in 2020 to 2 % (176/8806) in 2024. The overall unsuccessful results (error, invalid & no result) were 6.48 %. The rate of unsuccessful results remained above the national target of < 5 % throughout the study periods. Conclusion and recommendation: The rate of

Indexed as

Amhara RegionMDR-TBUnsuccessful resultsXpert MTB-RIF-Ultra

Identifiers

PMID40351513
PMCPMC12063118

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.